Related Party Transactions	6 Months Ended
Jun. 30, 2022
Related Party Transactions [Abstract]
Related Party Transactions	2. Related Party Transactions Frazier is a principal stockholder of the Company and is represented on the Company’s board of directors. From January 8, 2019 (inception) to June 30, 2022, the Company and Frazier reimbursed each other for various goods and services, including personnel related expenses, travel, insurance, facilities and other various overhead and administrative expenses. As of June 30, 2022 and December 31, 2021, the Company had outstanding amounts due to Frazier of $8,000 and $22,000, respectively, related to these shared operating expenses. For the three months ended June 30, 2022 and 2021 and the six months ended June 30, 2022 and 2021, the Company incurred $8,000, $0.2 million, $34,000 and $0.4 million, respectively, of shared operating expenses. Mountain Field LLC (“Mountain Field”) is an entity owned by a former member of the Company’s board of directors. From January 8, 2019 (inception) to June 30, 2022, the Company charged Mountain Field for various personnel related and other administrative expenses associated with the operations of Mountain Field. These shared expenses were allocated based on time incurred by personnel. For the three months ended June 30, 2022 and 2021 and the six months ended June 30, 2022 and 2021, the Company charged Mountain Field $0, $0, $0 and $5,000, respectively, for shared expenses. On July 2, 2021, the Company entered into a license agreement with Takeda pursuant to which it was granted an exclusive sublicensable, royalty-bearing license (the “Takeda License”) to commercialize HIL-214 pharmaceutical products for all human uses on a worldwide basis outside of Japan. In connection with the Takeda License, Takeda became a related party stockholder with representation on the Company’s board of directors. In March 2022, the Company paid Takeda an aggregate $2.5 million contingent payment upon the release of certain drug products and the completion of certain regulatory activities, which have no alternative future use, and was recorded as in-process research and development in the Company’s condensed consolidated statement of operations for the three months ended March 31, 2022. The Company and Takeda are party to a Transitional Services Agreement (“TSA”) under which the Company is obligated to pay Takeda for certain services, including pass-through costs, related to research and development and regulatory assistance services, oversight and management of ongoing clinical and research studies, and maintenance of third-party vendor contracts. For the three and six months ended June 30, 2022, the Company incurred $0.2 million and $1.6 million, respectively, of research and development expenses for Takeda’s services. As of June 30, 2022, the Company had $1.6 million and $0.8 million, respectively, of accounts payable and accrued expenses due to Takeda. As of December 31, 2021, the Company had $4.9 million of accrued expenses due to Takeda.

Related Party Transactions

6 Months Ended

Jun. 30, 2022

2. Related Party Transactions

Frazier is a principal stockholder of the Company and is represented on the Company’s board of directors. From January 8, 2019 (inception) to June 30, 2022, the Company and Frazier reimbursed each other for various goods and services, including personnel related expenses, travel, insurance, facilities and other various overhead and administrative expenses. As of June 30, 2022 and December 31, 2021, the Company had outstanding amounts due to Frazier of $8,000 and $22,000, respectively, related to these shared operating expenses. For the three months ended June 30, 2022 and 2021 and the six months ended June 30, 2022 and 2021, the Company incurred $8,000, $0.2 million, $34,000 and $0.4 million, respectively, of shared operating expenses.

Mountain Field LLC (“Mountain Field”) is an entity owned by a former member of the Company’s board of directors. From January 8, 2019 (inception) to June 30, 2022, the Company charged Mountain Field for various personnel related and other administrative expenses associated with the operations of Mountain Field. These shared expenses were allocated based on time incurred by personnel. For the three months ended June 30, 2022 and 2021 and the six months ended June 30, 2022 and 2021, the Company charged Mountain Field $0, $0, $0 and $5,000, respectively, for shared expenses.

On July 2, 2021, the Company entered into a license agreement with Takeda pursuant to which it was granted an exclusive sublicensable, royalty-bearing license (the “Takeda License”) to commercialize HIL-214 pharmaceutical products for all human uses on a worldwide basis outside of Japan. In connection with the Takeda License, Takeda became a related party stockholder with representation on the Company’s board of directors. In March 2022, the Company paid Takeda an aggregate $2.5 million contingent payment upon the release of certain drug products and the completion of certain regulatory activities, which have no alternative future use, and was recorded as in-process research and development in the Company’s condensed consolidated statement of operations for the three months ended March 31, 2022.

The Company and Takeda are party to a Transitional Services Agreement (“TSA”) under which the Company is obligated to pay Takeda for certain services, including pass-through costs, related to research and development and regulatory assistance services, oversight and management of ongoing clinical and research studies, and maintenance of third-party

vendor contracts. For the three and six months ended June 30, 2022, the Company incurred $0.2 million and $1.6 million, respectively, of research and development expenses for Takeda’s services. As of June 30, 2022, the Company had $1.6 million and $0.8 million, respectively, of accounts payable and accrued expenses due to Takeda. As of December 31, 2021, the Company had $4.9 million of accrued expenses due to Takeda.